Glenmark gets FDA nod for generic of psoriasis medication Enstilar Foam

Glenmark Pharmaceuticals has secured tentative approval from the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%.

The product is the generic version of Enstilar Foam, 0.005%|0.064%, a psoriasis medication from Leo Pharma.

For the 12-month period ending March 2022, the Enstilar Foam, 0.005%|0.064% market achieved annual sales of around $115.2 million, as per IQVIA sales data.

The current portfolio of Glenmark Pharmaceuticals consists of 174 products authorized for distribution in the American marketplace and 48 abbreviated new drug applications (ANDAs) pending approval with the FDA.

Related Posts

Share This